Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

ClinicalTrials.gov ID: NCT03125460

Public ClinicalTrials.gov record NCT03125460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Study identification

NCT ID
NCT03125460
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Cepheid
Industry
Enrollment
424 participants

Conditions and interventions

Conditions

Interventions

Device

Eligibility (public fields only)

Age range
40 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2016
Primary completion
Jan 31, 2019
Completion
Apr 30, 2019
Last update posted
Feb 6, 2020

2016 – 2019

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
PAVA Palo Alto California 94304
The Urology Center of Colorado, P.C. Denver Colorado 80211
Urology Associates, P.C. Englewood Colorado 80113
North Idaho Urology Coeur d'Alene Idaho 83814
Idaho Urologic Institute Meridian Idaho 83642
UroPartners Melrose Park Illinois 60160
Five Valleys Urology Missoula Montana 59808
Weill Cornell Medicine New York New York 10065-4896
Stephenson Cancer Center Oklahoma City Oklahoma 73104
UT Southwestern Dallas Texas 75390
Virginia Urology Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03125460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 6, 2020 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03125460 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →